Expand Trial Footprints Without Expanding Cryopreservation Risk

Transitioning cell therapy starting material from fresh to cryopreserved is often viewed as the definitive step toward controlling operational variability. However, treating cryopreservation as an isolated event separated from downstream logistics introduces hidden vulnerabilities as trial footprints expand. Variables like transport duration, pre-processing holds, and localized handling can compromise starting material long before manufacturing begins.

Integrating cryopreservation directly into an end-to-end supply chain framework stabilizes critical inputs, harmonizes handoffs across clinical sites, and protects material integrity as programs scale. Seamlessly aligning collection, cryopreservation, and transport establishes the operational control required to expand multi-center clinical trials without compounding bio-preservation risks.

Explore the full analysis to optimize early supply chain strategy.